dexamethasone,lenalidomide,carfilzomib
amgen
['mmsm', 'atlas']
the atlas trial presented at #asco22
-given design (3 drugs maint, and pfs as endpoint), answer was obvious.
-low power to detect any survival difference
-no quality of life presented, suspect would be worse if properly measured in krd arm
-please don t adopt in practice! #mmsm 
Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own.